Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

NCT05932667 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Financial partner providing study drug could no longer support the trial

Conditions

Advanced or Metastatic Breast Cancer

Interventions

DRUG: Milademetan
BEHAVIORAL: Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)

Sponsor

Institut Curie

Collaborators

[object Object]